Ractigen’s saRNA therapeutic named US orphan drug for Duchenne and Becker muscular dystrophies

Aug. 23, 2024

Ractigen Therapeutics Co. Ltd.’s small activating RNA (saRNA) therapeutic, RAG-18, has been awarded U.S. orphan drug designation for the treatment of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy.

BioWorld Science Regulatory Neurology/psychiatric FDA Orphan drug

Today's news in brief

BioWorld

BioWorld briefs for April 8, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 8, 2025.

Pfizer’s PF-07853578 is candidate to treat MASH

BioWorld Science

The I148M mutation in the PNPLA3 gene, which encodes patatin-like phospholipase domain-containing protein 3, is known to confer risk of fatty liver, cirrhosis and...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

PFA non-inferior, even superior, to cryoablation for paroxysmal AF

BioWorld MedTech

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance...